spacer
home > ebr > autumn 2009 > investigating interactions
PUBLICATIONS
European Biopharmaceutical Review

Investigating Interactions

 

As a result of scientific efforts over the last few decades, the Protein Data Bank (PDB) library now contains descriptions of more than 48,000 high-resolution biomolecular structures (1). In addition, characterisation data for more than 38,000 of the estimated 300,000 protein-protein interactions in humans has been collected (2). This information is critical to our understanding of interactions between proteins and in the investigation of the effects of these interactions, from academic research to drug discovery and development. Based on the report by Prasad et al, it can be calculated that only around six per cent of the identified interactions have been confirmed in vivo and with the use of several in vitro techniques (2). Thus, although a significant number of interactions are already well-characterised, there is still a need for additional experimental verification.

As well as the need for investigation of protein structure-function relationships and the mapping of the interactome to increase our biological understanding, there is also a growing demand from regulatory authorities to employ orthogonal approaches to biotherapeutic discovery and development. Complementary methods are needed to enable researchers to validate and verify interaction data, and to make confident conclusions and decisions in the drug development process.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thomas Lundbäck is a Senior Project Manager at GE Healthcare, Life Sciences. He recently joined GE Healthcare from Biovitrum, where he held the positions of project leader and principal scientist, implementing different biophysical techniques. Thomas has a PhD in biophysical chemistry from the Karolinska Institute in Stockholm, Sweden. He is also a member of the Industrial Research Committee at the Royal Swedish Academy of Engineering Sciences (IVA), which represents research areas of future strategic interest for Swedish industry.
spacer
Thomas Lundbäck
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Nasal Drug Delivery with a Focus on Chronic Rhino-Sinusitis

Aptar Pharma

Aptar Pharma have hosted a scientific roundtable on “Nasal drug delivery with a focus on chronic rhino‑sinusitis”. This international scientific forum was held in Paris, France on November 13th 2012. The roundtable was organized to explore and exchange views on the science of various forms of sinusitis and its related unmet medical needs.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement